Results from this study should be taken into consideration and interrogated further in future studies, with the goal of attaining therapeutic synergy between IL-2 agonists and immune checkpoint inhibitors in patients with unresectable/metastatic melanoma. The gene discussed is IL2; the disease is metastatic melanoma.